The Patent Finder

CuRNA, Inc.

Also on record
Records under this name other than the patents CuRNA, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 51 patents it holds.

Back to CuRNA, Inc.

PatentTitleStatus Expires Confidence
US 8,318,690Treatment of hemoglobin (HBF/HBG) related diseases by inhibition of natural antisense transcript to HBF/HBG
Formerly held
In force
 · From the USPTO record
In forceFrom the USPTO record
US 10,214,745Treatment of Brain Derived Neurotrophic Factor (BDNF) Related Diseases by Inhibition of Natural Antisense Transcript to BDNF
Formerly held
In force
 · Medium confidence
In forceMedium confidence
US 10,113,166Treatment of Filaggrin (FLG) Related Diseases by Modulation of FLG Expression and Activity
Grace period ended
 · Low confidence
Grace period endedLow confidence
US 11,408,004Treatment of Sirtuin (SIRT) Related Diseases by Inhibition of Natural Antisense Transcript to a Sirtuin (SIRT)
Lapsed on the fee record
Ended Aug 9, 2026 · High confidence
Lapsed on the fee recordEnded Aug 9, 2026High confidence
US 10,036,014Treatment of Down Syndrome Gene Related Diseases by Inhibition of Natural Antisense Transcript to a Down Syndrome Gene
Lapsed on the fee record
Ended Jul 31, 2026 · High confidence
Lapsed on the fee recordEnded Jul 31, 2026High confidence
US 8,791,087Treatment of 'C Terminus of HSP70-Interacting Protein' (CHIP) Related Diseases by Inhibition of Natural Antisense Transcript to Chip
Lapsed on the fee record
Ended Jul 29, 2026 · High confidence
Lapsed on the fee recordEnded Jul 29, 2026High confidence
US 11,390,868Treatment of Filaggrin (FLG) Related Diseases by Modulation of FLG Expression and Activity
Lapsed on the fee record
Ended Jul 19, 2026 · High confidence
Lapsed on the fee recordEnded Jul 19, 2026High confidence
US 11,339,394Treatment of collagen gene related diseases by inhibition of natural antisense transcript to a collagen gene
Lapsed on the fee record
Ended May 24, 2026 · From the USPTO record
Lapsed on the fee recordEnded May 24, 2026From the USPTO record
US 9,970,008Treatment of atonal homolog 1 (ATOH1) related diseases by inhibition of natural antisense transcript to ATOH1
Lapsed on the fee record
Ended May 15, 2026 · From the USPTO record
Lapsed on the fee recordEnded May 15, 2026From the USPTO record
US 9,957,503Treatment of LCAT gene related diseases by inhibition of a natural antisense transcript to LCAT
Lapsed on the fee record
Ended May 1, 2026 · From the USPTO record
Lapsed on the fee recordEnded May 1, 2026From the USPTO record
10 of 62 patents shown.
Pro members see all 62.
Pro members: see all 62 patents
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited